177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study (Q63342918)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Emanuela Scarpi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Federica Matteucci

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Maddalena Sansovini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Alice Ambrosetti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Stefano Severi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Manuela Monti

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Caterina Donati

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Annarita Ianniello

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Dino Amadori

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

11 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Nuclear Medicine and Molecular Imaging

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

1845-1851

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615468%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00259-014-2735-5

10 March 2020

exact match

0 references

cites work

Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate

1 reference

12 December 2020

End-stage renal disease after treatment with 90Y-DOTATOC.

1 reference

12 December 2020

18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors

1 reference

12 December 2020

Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy

1 reference

12 December 2020

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

1 reference

12 December 2020

Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors

1 reference

12 December 2020

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

1 reference

12 December 2020

Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting

1 reference

12 December 2020

MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.

1 reference

12 December 2020

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

12 December 2020

Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment

1 reference

12 December 2020

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

12 December 2020

Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.

1 reference

12 December 2020

Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours

1 reference

12 December 2020

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

1 reference

12 December 2020

The epidemiology of gastroenteropancreatic neuroendocrine tumors.

1 reference

12 December 2020

Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary

1 reference

12 December 2020

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

1 reference

12 December 2020

Management of neuroendocrine tumours

1 reference

12 December 2020

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours

1 reference

12 December 2020

The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems

1 reference

12 December 2020

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

1 reference

12 December 2020

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

12 December 2020

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

1 reference

12 December 2020

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

1 reference

12 December 2020